Published in J Clin Microbiol on September 01, 1993
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev (1995) 8.81
Cryptococcus gattii infections. Clin Microbiol Rev (2014) 1.55
Genetic relatedness of Cryptococcus neoformans clinical isolates grouped with the repetitive DNA probe CNRE-1. J Clin Microbiol (1995) 1.05
New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS (2013) 0.98
Cryptococcus neoformans meningitis with negative cryptococcal antigen: Evaluation of a new immunochromatographic detection assay. New Microbes New Infect (2014) 0.90
Elimination of false-positive serum reactivity in latex agglutination test for cryptococcal antigen in human immunodeficiency virus-infected population. J Clin Microbiol (1994) 0.90
Immunoreactivity of cryptococcal antigen is not stable under prolonged incubations in human serum. J Clin Microbiol (2004) 0.85
In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies. Infect Immun (1999) 0.82
Sensitivity of sandwich enzyme-linked immunosorbent assay for Cryptococcus neoformans polysaccharide antigen is dependent on the isotypes of the capture and detection antibodies. J Clin Microbiol (1995) 0.79
Disseminated cryptococcosis presenting as mediastinal and hilar lymphadenopathy in an immunocompetent patient. Respirol Case Rep (2016) 0.78
Cryptosporidium antigen detection in human feces by reverse passive hemagglutination assay. J Clin Microbiol (1995) 0.76
Cryptococcal Infection of the Ventriculoperitoneal Shunt in an Immunocompetent Patient. Am J Case Rep (2016) 0.75
Integrated therapy for HIV and cryptococcosis. AIDS Res Ther (2016) 0.75
Comparison of Antigen Detection and Nested PCR in CSF Samples of HIV Positive and Negative Patients with Suspected Cryptococcal Meningitis in a Tertiary Care Hospital. J Clin Diagn Res (2016) 0.75
Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol (1982) 6.78
Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med (1989) 6.29
Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide. Infect Immun (1971) 5.45
Diagnosis of cryptococcal meningitis. Value of immunologic detection of cryptococcal antigen. N Engl J Med (1971) 4.07
DETECTION OF CRYPTOCOCCUS NEOFORMANS ANTIGEN IN BODY FLUIDS BY LATEX PARTICLE AGGLUTINATION. Proc Soc Exp Biol Med (1963) 3.61
Control for rheumatoid factor in the latex test for cryptococcosis. Am J Clin Pathol (1971) 3.47
Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med (1986) 3.34
Comparison of the PREMIER cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens. J Clin Microbiol (1991) 2.42
Extensive allelic variation in Cryptococcus neoformans. J Clin Microbiol (1992) 2.06
Commercial cryptococcal latex kit: clinical evaluation in a medical center hospital. J Clin Microbiol (1978) 1.89
Cryptococcosis. Infect Dis Clin North Am (1989) 1.87
New cause for false-positive results with the cryptococcal antigen test by latex agglutination. J Clin Microbiol (1985) 1.70
Comparison of three commercial cryptococcal latex kits for detection of cryptococcal antigen. J Clin Microbiol (1983) 1.58
Experience with the use of pronase to eliminate interference factors in the latex agglutination test for cryptococcal antigen. J Clin Microbiol (1988) 1.54
DETECTION OF CRYPTOCOCCAL POLYSACCHARIDE IN SERUM AND SPINAL FLUID: VALUE IN DIAGNOSIS AND PROGNOSIS. Trans Assoc Am Physicians (1964) 1.41
Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol (1991) 1.38
False-negative cryptococcal antigen test. JAMA (1980) 1.35
Evaluation of a monoclonal antibody-based latex agglutination test for diagnosis of cryptococcosis: comparison with two tests using polyclonal antibodies. J Clin Microbiol (1992) 1.20
Serodiagnosis of candidiasis, aspergillosis, and cryptococcosis. Clin Infect Dis (1992) 1.07
False-positive reactions in the latex agglutination test for Cryptococcus neoformans antigen. J Clin Microbiol (1991) 1.02
Cryptococcal antigen test. JAMA (1981) 0.85
Postzone v prozone. JAMA (1982) 0.80
Urease as a virulence factor in experimental cryptococcosis. Infect Immun (2000) 3.53
Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun (1995) 3.43
Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun (2000) 3.42
Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol (1999) 3.38
Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A (2001) 3.37
Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol (2001) 3.34
Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet (1993) 3.34
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis (1994) 2.87
Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J Clin Microbiol (1994) 2.43
Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect Immun (1994) 2.41
Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics (2001) 2.40
Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol (1997) 2.25
Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J Clin Microbiol (1997) 2.19
Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans. Infect Immun (1996) 2.15
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun (1998) 2.12
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun (1995) 2.09
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology (2001) 2.08
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun (1994) 2.07
Extensive allelic variation in Cryptococcus neoformans. J Clin Microbiol (1992) 2.06
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother (1994) 2.00
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother (1997) 1.89
Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A (1993) 1.86
Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun (1994) 1.83
Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev (1998) 1.82
Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun (1995) 1.79
Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect Immun (2000) 1.79
Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme-linked immunosorbent spot assay for detection of mycobacteria. J Clin Microbiol (1996) 1.76
T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci U S A (1997) 1.72
Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev (2001) 1.72
Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol (1996) 1.71
An aminoglycoside disk sensitivity test for use with enterococci. J Antimicrob Chemother (1982) 1.71
Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun (1995) 1.70
Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect Immun (1997) 1.69
Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol (1995) 1.67
Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet (1992) 1.67
Decreased susceptibility of melanized Cryptococcus neoformans to UV light. Appl Environ Microbiol (1994) 1.65
Laccase of Cryptococcus neoformans is a cell wall-associated virulence factor. Infect Immun (2001) 1.64
Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun (1998) 1.63
Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun (1999) 1.60
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med (1997) 1.60
Melanization of Cryptococcus neoformans in murine infection. Mol Cell Biol (1999) 1.59
Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci U S A (1998) 1.58
Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell (2005) 1.58
Karyotype instability in Cryptococcus neoformans infection. J Clin Microbiol (1996) 1.53
Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob Agents Chemother (1994) 1.53
Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol (2005) 1.53
J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J Infect Dis (1996) 1.51
Melanisation of Cryptococcus neoformans in human brain tissue. Lancet (2000) 1.50
Serum therapy for Cryptococcal meningitis. Clin Infect Dis (1995) 1.50
Melanin as a potential cryptococcal defence against microbicidal proteins. Med Mycol (1999) 1.48
Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother (1994) 1.48
The antibody response to fungal melanin in mice. J Immunol (1998) 1.42
Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J Immunol (2001) 1.42
Isolation and serological analyses of fungal melanins. J Immunol Methods (2000) 1.41
Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J Immunol (2000) 1.39
Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J Clin Invest (2001) 1.38
The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin Diagn Lab Immunol (1998) 1.37
Prevalence of Cryptococcus neoformans var. neoformans (Serotype D) and Cryptococcus neoformans var. grubii (Serotype A) isolates in New York City. J Clin Microbiol (2000) 1.36
Extracellular proteinase activity of Cryptococcus neoformans. Clin Diagn Lab Immunol (1996) 1.36
Prevention of growth of Yersinia enterocolitica in blood by polyester fiber filtration. Transfusion (1992) 1.34
Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect Immun (2001) 1.32
Detection of melanin-like pigments in the dimorphic fungal pathogen Paracoccidioides brasiliensis in vitro and during infection. Infect Immun (2001) 1.31
Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J Infect Dis (1998) 1.30
Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice. J Infect Dis (1998) 1.30
Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Infect Immun (1997) 1.27
Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci (1994) 1.27
Fungal morphogenesis and virulence. Med Mycol (2000) 1.26
Cryptococcus neoformans survive and replicate in human microglia. Lab Invest (1995) 1.26
Melanization affects susceptibility of Cryptococcus neoformans to heat and cold. FEMS Microbiol Lett (1997) 1.26
Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob Agents Chemother (1994) 1.26
Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect Immun (1999) 1.26
Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev (1998) 1.26
Genetic relationship between Cryptococcus neoformans var. neoformans strains of serotypes A and D. J Clin Microbiol (1998) 1.26
Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob Agents Chemother (1995) 1.24
Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models. Antimicrob Agents Chemother (2004) 1.24
Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis (1996) 1.24
Evidence that Cryptococcus neoformans is melanized in pigeon excreta: implications for pathogenesis. Infect Immun (1999) 1.23
Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans. Infect Immun (1998) 1.23
DNA packing in filamentous bacteriophages. Annu Rev Biophys Biophys Chem (1988) 1.21
Immune complexes increase nitric oxide production by interferon-gamma- stimulated murine macrophage-like J774.16 cells. J Leukoc Biol (1995) 1.21
Expression of a Mycobacterium tuberculosis arabinomannan antigen in vitro and in vivo. Infect Immun (2001) 1.21
Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am J Pathol (1996) 1.20
Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans. J Exp Med (1996) 1.19
Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect Immun (2001) 1.19
Extracellular proteins of Cryptococcus neoformans and host antibody response. Infect Immun (1997) 1.17
Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism. J Exp Med (1994) 1.17
The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis (2000) 1.16
Glyphosate inhibits melanization of Cryptococcus neoformans and prolongs survival of mice after systemic infection. J Infect Dis (2001) 1.15
Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations. Antimicrob Agents Chemother (1999) 1.15
Identification and characterization of the Cryptococcus neoformans phosphomannose isomerase-encoding gene, MAN1, and its impact on pathogenicity. Mol Microbiol (2001) 1.15
Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice. Infect Immun (1998) 1.14